论文部分内容阅读
应用免疫放射分析法(IRMA)检测327例肺癌,297例肺部良性疾病患者CYFRA21-1的血清水平,肺癌组水平16.9±8.4ng/ml,非肿瘤组水平1.9±1.6ng/ml(p<0.001)。肺癌阳性率62.4％,良性疾患阳性率5％。测定灵敏度为62.4％,特异性为94.5％,准确率77.9％,结果均好于CEA、NSE、CA-242。肺癌病人随病期的增加,血清CYFRA21-1含量也随之上升(P<0.02)。对8例肺癌手术病人和10例化疗病人含量变化分析,在手术3～5周后,血清含量由术前的6.4±3.1ng/ml,降到1.8±0.6ng/ml,10例化疗病人,其中8例血清含量均有降低,由17.4±9ng/ml降至4.9±2.0ng/ml,临床证实均有良好的治疗效果,另2例临床证实治疗无效,血清CYFRA21-1水平相应增高。
The serum levels of CYFRA21-1 in 327 patients with lung cancer and 297 patients with benign lung diseases were measured by immunoradiometric assay (IRMA), 16.9±8.4ng/ml in lung cancer group and 1.9±1.6ng/ml in non-tumor group (p< 0.001). The positive rate of lung cancer was 62.4% and the positive rate of benign disease was 5%. The sensitivity was 62.4%, the specificity was 94.5%, and the accuracy rate was 77.9%. The results were all better than CEA, NSE and CA-242. In patients with lung cancer, the serum CYFRA21-1 level also increased with the increase of the disease period (P<0.02). The analysis of changes in the levels of 8 patients with lung cancer and 10 patients with chemotherapy showed that serum levels decreased from 6.4±3.1ng/ml preoperatively to 1.8±0.6ng/ml 3 to 5 weeks after surgery and 10 patients received chemotherapy. Among them, serum levels in 8 patients all decreased from 17.4±9 ng/ml to 4.9±2.0 ng/ml, clinically proven to have good therapeutic effects, and the other 2 patients clinically proven to be ineffective in treatment, serum CYFRA21-1 levels increased accordingly.